References
- ELITEK (rasburicase) prescribing information, sanofi-aventis U.S.
- Data on file. sanofi-aventis U.S.
- Coiffier B, Altman A, Ching-Hon P, Younes A, Cario MS. Guidelines for the
management of pediatric and adult tumor lysis syndrome: an evidence-based review.
J Clin Oncol. 2008;26:2767-2778.
- Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and
classification. Br J Haematol. 2004;127(1):3-11.
- Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical,
and Laboratory Examinations. 3rd ed. Boston, MA: Butterworth Publishers; 1990:677-899.
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=cm. Accessed August 17, 2010.
- Tsimberidou A-M, Keating MJ. Hyperuricemic syndromes in cancer patients.
In: Ronco C, Rodeghiero F, eds. Hyperuricemic Syndromes: Pathophysiology and Therapy.
Contrib Nephrol. Basel, Switzerland: Karger; 2005;147:47-60.
- Bishop MR, Coccia PF. Tumor lysis syndrome. In: Abeloff MD, et al, eds.
Clinical Oncology. 2nd ed. New York, NY: Churchill Livingstone; 2000:750-753.
- Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management.
Pediatric Nephrol. 1995;9:206-212.
- Rituxan [package insert]. San Francisco, CA: Genentech, Inc.; 2010.
- Revlimid [package insert]. Summit, NJ: Celgene Corporation; 2009.
- Velcade [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc.;
2009.
- Treanda [package insert]. Frazer, PA: Cephalon, Inc.; 2010.
- Food and Drug Administration Oncologic Drugs Advisory Committee. Arzerra™
(ofatumumab) for Intravenous Use: Injection briefing document. http://www.fda.gov/downloads/AdvisoryCommittees
/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM163891.pdf.
Accessed July 29, 2010.
- Clolar [package insert]. San Antonio, TX: Genzyme Corporation; 2009.
- VinCRIStine Sulfate [package insert]. Lake Forest, IL: Hospira, Inc.; 2007.
- Purinethol [package insert]. Greenville, NC: DSM Pharmaceuticals, Inc.;
2003.
- Elspar [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2005.
- Adriamycin [package insert]. New York, NY: Pfizer Inc.; 2006.
- Adams VR, Liewer S. Guide to the Administration and Use of Cancer Therapeutic
Agents 2010. New York, NY: McMahon Publishing; 2010.
- Ellence [package insert]. New York, NY: Pfizer Inc.; 2007.
- Mustargen [package insert]. Deerfield, IL: Lundbeck, Inc.; 2009.
- Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome.
Nat Clin Pract Oncol. 2006;3:438-447.
- Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison
between rasburicase and allopurinol in children with lymphoma or leukemia at high
risk for tumor lysis. Blood. 2001; 97:2998-3003.
- Cheson BD, Dutcher, BS. Managing malignancy-associated hyperuricemia with
rasburicase. J Support Oncol. 2005;3:117-124.
- Aloprim [package insert]. Catalytica Pharmaceuticals, Inc.; 1999.
- Zyloprim [package insert]. DSM Pharmaceuticals, Inc.; 2003.
- Cairo MS, et al. Presented at: 38th Annual Meeting of ASCO; May 18-21, 2002;
Orlando, Fla. Abstract 2901.
- Wetzstein GA. Tumor Lysis Syndrome: A Treatment Guide. New York,
NY: McMahon Publishing Group; 2000.
- Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol.
2000;27:322-334.
- Stucky LA. Acute tumor lysis syndrome: assessment and nursing implications.
Oncol Nurs Forum. 1993;20:49-59.
- Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW. Acute tumor
lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma:
a case report and review of the literature. Cancer. 1999;85:1055-1059.
- Altman A. Acute tumor lysis syndrome. Semin Oncol. 2001;28 (suppl
5):3-8.
- Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing
and/or treating tumor lysis syndrome: biochemical and clinical relevance of hyperuricemia.
Curr Pharmaceut Design. 2005;11:4177-4185.
- Morris JC, Holland JF. Oncologic emergencies. In: Bast RC Jr, Hellman S,
Rosenberg SA, eds. Holland-Frei Cancer Medicine. 5th ed. Hamilton, Ontario:
B.C. Decker, Inc; 2000:2446-2449.
- Stapleton FB, Strother DR, Roy S III, Wyatt RJ, McKay CP, Murphy SB. Acute
renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell
acute lymphoblastic lymphoma. Pediatrics. 1988;82:863-869.
- Pui C-H, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the
prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma.
J Clin Oncol. 2001;19:697-704.
- Pui C-H, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase)
in the prevention and treatment of malignancy-associated hyperuricemia in pediatric
and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-1509.
Additional References:
Pui C-H, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment
of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813-1816.
Farber MS. Pharmacoeconomic considerations in the management of acute tumor lysis
syndrome. Semin Oncol. 2001;28(2 suppl 5):19-22.
Warrell RP Jr. Metabolic emergencies. In: DeVita VT Jr, Hellman S, Rosenberg SA,
eds. Cancer Principles and Practice of Oncology. 5th ed. Philadelphia, PA:
Lippincott-Raven Publishers; 1997;2:2486-2500.
Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol:
intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol.
2000;18:1758-1763.
Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F. Advances in the management
of Malignancyassociated hyperuricemia. Br J Cancer. 1998;77 (suppl 4):18-20.
Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RAK. Hyperuricemia and renal insufficiency
associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney
Dis. 1999;34:1-6.
Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome:
a review of 37 patients with Burkitt’s lymphoma. Am J Med. 1980;68:486-491.
Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell
acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric
Oncology Group study. J Clin Oncol.1996;14:1252-1261.